Citations

Showing 10 of 108104 citations.

Toxicity following palliative radiation therapy for painful metastatic bone lesions.
Jenkins, Mikayla, Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , DeVries, Matthew , Pacitti, Delaney, May, Jackson, Patibandla, Aditya, White, Launia J. , Spaulding, Aaron , Naessens, James M. , Spaulding, Aaron , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 126-126

10.1200/jco.2018.36.34_suppl.126 Get It

126 Background: Palliative radiation treatment (pRT) is a common and effective treatment for patients with symptomatic bone metastases. However, patients receiving RT for bone metastases often may have a poor performance status and are more likely to experience toxicity during or after treatment. This study aims to investigate the number and type of toxicity event occurring during or after pRT for bone metastases. Methods: Patients treated with RT for bone metastases at Mayo Clinic from 2007 to 2016 were included in this study. Demographic, disease, treatment, and toxicity information were collected. Specifically, toxicity events were identified as emergency department (ED) visits and inpatient hospitalization (IH) within 90 days, breaks in treatment >4 days, and excessive 30 day financial toxicity defined as standardized Medicare costs >1 standard deviation above the mean. RT treatment was compared by dose and fractionation via descriptive statistics. Results: A total of 538 patients treated with pRT were identified, 124 receiving 8Gy x1, 204 receiving 4Gy x5, and 210 receiving 3Gy x10. Patients with breast and prostate cancer were most likely to be treated with 3Gy x10 and patients with GI and Lung cancer were most likely to be treated with 8Gy x1. A description of the patient characteristics and toxicities are shown in Table 1. For 8Gy x1, 4Gy x5, and 3Gy x10 breaks in treatment were rare (0%, 2%, and 3.3%), ED visits (15%, 24%, & 28%), IH (12%, 23%, & 19%), and financial toxicity (13%, 18%, & 21%) were common. A total of 22.6%, 27.5%, and 38.6% of patients were alive two years following pRT from each group. Conclusions: Toxicity during or shortly after pRT of bone metastases is common. This study confirms that additional steps should be taken to monitor and mitigate toxicity in this vulnerable patient group. [Table: see text]
Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer.
Roeland, Eric , Ruddy, Kathryn J. , Binder, G. , Bailey, William L., Amari, Diana T., Kanakamedala, Hemanth, Navari, Rudolph M. , Roeland, Eric J , Nipp, Ryan David

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 112-112

10.1200/jco.2018.36.34_suppl.112 Get It

112 Background: Reducing hospitalizations for chemotherapy-related toxicities represents an opportunity to improve both the quality and cost of cancer treatment. Nausea and vomiting (NV) account for almost 10% of “avoidable” toxicity-related post-chemotherapy hospitalizations (2016 Medicare data). We sought to evaluate the event cost of NV-related hospitalizations among patients with cancer from a US payer perspective. Methods: From a large US claims database (Truven MarketScan), we identified hospitalizations with NV as the primary diagnosis and cancer as a secondary diagnosis (01/2011-06/2017). This method increases specificity for NV as the principal hospitalization factor, while underreporting the prevalence of NV as a contributory factor. To determine event costs, we evaluated hospital and other reimbursement during the hospitalization. To explore subgroup differences, we stratified results by tumor type, payer type, admission route, receipt of highly emetogenic chemotherapy (HEC; 2017 definition includes carboplatin AUC ≥4) and antiemetic prophylaxis. We adjusted all costs to 2017 US dollars. Results: Among 918,192 hospitalizations involving cancer, we identified 80,995 with both NV and a cancer diagnosis code. Of these, 5,293 had NV as the primary diagnosis and 62 lacked cost data. Patients (mean age = 57.7±16.2) were 67% female. Median hospital length of stay was 4 days and mean cost per hospitalization was $15,085. Non-Medicare admissions (82%) had a higher mean cost vs. Medicare ($15,737 vs. $12,111, p < 0.01). We found < $1,000 difference between the highest and lowest cost per hospitalization among the 6 most common tumor types. We found the 65% of patients with a chemotherapy claim ≤30 days prior to hospitalization had costs of $13,882 per event. Among the 45% of chemotherapies that were HEC, > 50% lacked an NK1 receptor antagonist as prophylaxis. Conclusions: The average cost of NV-related hospitalizations among patients with cancer exceeds $15,000 per event, highlighting the need to effectively address this symptom. Roughly half the hospitalizations involved HEC, with over half of those patients not receiving guideline-based antiemetic prophylaxis.
Pancreatic tumor cell metastasis is restricted by MT1-MMP binding protein MTCBP-1
Li, Qiang , Cao, Hong , Chen, Jing , Weller, Shaun G. , Krueger, Eugene W. , Zhang, Lizhi , Razidlo, Gina L. , McNiven, Mark A. , Qiang, Li , Razidlo, Gina L , Chen, Jing

Mayo Clinic

Journal of Cell Biology | November 28, 2018 | Volume: 218 | Issue: 1 | Pages: 317-332

10.1083/jcb.201802032 | PMID 30487181 Get It

The process by which tumor cells mechanically invade through surrounding stroma into peripheral tissues is an essential component of metastatic dissemination. The directed recruitment of the metalloproteinase MT1-MMP to invadopodia plays a critical role in this invasive process. Here, we provide mechanistic insight into MT1-MMP cytoplasmic tail binding protein 1 (MTCBP-1) with respect to invadopodia formation, matrix remodeling, and invasion by pancreatic tumor cells. MTCBP-1 localizes to invadopodia and interacts with MT1-MMP. We find that this interaction displaces MT1-MMP from invadopodia, thereby attenuating their number and function and reducing the capacity of tumor cells to degrade matrix. Further, we observe an inverse correlation between MTCBP-1 and MT1-MMP expression both in cultured cell lines and human pancreatic tumors. Consistently, MTCBP-1–expressing cells show decreased ability to invade in vitro and metastasize in vivo. These findings implicate MTCBP-1 as an inhibitor of the metastatic process.
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Leiter, Lawrence A. , Kallend, David , Wright, R. Scott , Landmesser, Ulf , Wijngaard, Peter, Kastelein, John J.P. , Ray, Kausik K. , Leiter, Lawrence A , Landmesser, Ulf , Ray, Kausik K , Teoh, Hwee

Mayo Clinic

Diabetes Care | November 28, 2018 | Volume: 42 | Issue: 1 | Pages: 173-176

10.2337/dc18-1491 | PMID 30487231 Get It

OBJECTIVE To evaluate the efficacy and safety of inclisiran by diabetes status. RESEARCH DESIGN AND METHODS ORION-1 (ClinicalTrials.gov, NCT02597127) randomized 501 subjects with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents and high LDL cholesterol (LDL-C), despite maximally tolerated LDL-C–lowering therapies, to one or two doses of placebo or inclisiran. Levels of lipids and proprotein convertase subtilisin/kexin type 9 (PCSK9) at baseline and day 180 were compared. RESULTS Inclisiran was associated with marked declines in LDL-C (median −28% to −52%, P &lt; 0.0001 and −28% to −55%, P &lt; 0.005 for all doses in the without- and with-diabetes groups, respectively) and PCSK9. The inclisiran-treated groups also had lower apolipoprotein B, non-HDL cholesterol, and lipoprotein(a) but higher HDL cholesterol. Inclisiran had an adverse profile similar to that of placebo, and adverse events were proportionally balanced in the baseline with- and without-diabetes groups. CONCLUSIONS PCSK9-targeted siRNA-driven strategies may provide a novel therapeutic option for managing dyslipidemia in the presence and absence of diabetes.
Social Media in Health Care: Time for Transparent Privacy Policies and Consent for Data Use and Disclosure
Petersen, Carolyn , Petersen, Carolyn , Lehmann, Christoph U.

Mayo Clinic

Applied Clinical Informatics | November 28, 2018 | Volume: 09 | Issue: 04 | Pages: 856-859

10.1055/s-0038-1676332 | PMID 30485880 Get It

Endoscopic Evaluation of the Eustachian Tube: assessment of a novel tool for grading Eustachian tube inflammation
McCoul, Edward D. , Mayer, Scott, Tabaee, Abtin, Bedrosian, Jeffrey C., Marino, Michael J. , McCoul, Edward D

Mayo Clinic

International Forum of Allergy & Rhinology | November 28, 2018 | Volume: 9 | Issue: 3 | Pages: 305-310

10.1002/alr.22252 | PMID 30485734 Get It

BackgroundSigns of inflammation are commonly encountered during endoscopic examination of the Eustachian tube (ET) region. The clinical applicability of these findings may be enhanced by use of a standardized assessment score.MethodsDigital video recordings were obtained of 50 nasal endoscopy examinations of the nasopharyngeal portion of the ET. Four fellowship‐trained rhinologists independently reviewed the videos with regard to specific physical findings: edema of the ET torus, erythema of the ET torus, exudate at the ET orifice, and presence of tubal tonsil. Scoring of this Endoscopic Evaluation of the Eustachian Tube (3ET) was reported using both 2‐point and 3‐point scales. Each reviewer repeated the scoring at a 10‐day interval. Interrater and intrarater agreement were calculated for each item and the total scores.ResultsInterrater and intrarater agreement were greater for the 3‐point scale than the 2‐point scale. Interrater agreement for overall instrument using the 3‐point scale was in the “acceptable” range for Krippendorff's alpha on both the first trial (0.6922) and second trial (0.7238). Intrarater agreement was generally “excellent” for individual items as well as the overall instrument.ConclusionThe 3ET comprising these 4 physical findings has acceptable interrater and intrarater reliability, and may be applied to future clinical studies of ET function and disease.
Assessment of rapid diagnostic tests and fourth‐generation Enzyme‐Linked Immunosorbent Assays in the screening of Human Immunodeficiency and Hepatitis B virus infections among first‐time blood donors in Libreville (Gabon)
Eko, Jean Marie, Bisseyé, Cyrille , Mombo, Landry Erik , Ndong, Jophrette Mireille Ntsame, Ekayeng, Schella Carlaye Mbina, Bengone, Calixte, Mbatchi, Bertrand, Nagalo, Bolni Marius , Nagalo, Bolni

Mayo Clinic

Journal of Clinical Laboratory Analysis | November 28, 2018 | Volume: 33 | Issue: 3 | Pages: No page available

10.1002/jcla.22824 | PMID 30485543 Get It

AbstractBackgroundBlood transfusion is a pathway for the transmission of blood‐borne pathogens such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV) from donors to recipients in most countries in sub‐Saharan Africa, including Gabon. The study aimed to compare the performance of four rapid diagnostic tests (RDTs: Alere DETERMINE, BIOSYNEX Exacto Pro HIV, MEDIFF HIV 1&2, and BIOSYNEX IMMUNOQUICK HBsAg) with results of 4th‐generation immunoenzymatic assays COBAS 6000 e601 and EVOLIS BioRad for the detection of HIV and hepatitis B surface antigen (HBsAg) in blood donors in Libreville, Gabon.MethodsReactive and nonreactive blood samples for HIV and HBsAg were selected using fourth‐generation ELISA COBAS 6000 e601 and EVOLIS BioRad. The sensitivities of RDTs were calculated using Epi Info version 6.04dfr (CDC, Atlanta, USA).ResultsSensitivities for the detection of HIV in blood donors were 90.9% for Alere DETERMINE, 81.8% for BIOSYNEX Exacto Pro HIV, and 81.8% for MEDIFF HIV 1&2 Serum/sang Total Cassette compared with COBAS 6000 e601. The sensitivity of Alere DETERMINE compared to the semi‐automated ELISA Bio‐Rad for HIV detection was 65.6%. The sensitivity of BIOSYNEX IMMUNOQUICK HBsAg compared to ELISA tests for the detection of HBsAg was 78.0%. The specificity of all RDTs for the detection of HIV and HBsAg was 100%.ConclusionAlere DETERMINE HIV‐1/2, MEDIFF HIV 1&2 Serum/sang Total Cassette, BIOSYNEX Exacto Pro HIV, and BIOSYNEX IMMUNOQUICK HBsAg are not recommended for determining whether donors qualify to donate blood because of their low sensitivity for the detection of HIV antibodies and HBsAg in blood donors in Gabon.
LIMA1: A Newly Identified Player in the Field of Cholesterol Control
Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | November 28, 2018 | Volume: 64 | Issue: 12 | Pages: 1792-1793

10.1373/clinchem.2018.294645 | PMID 32100865 Get It

Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis
Ebadi, Maryam , Bhanji, Rahima A. , Lytvyak, Ellina , Mason, Andrew L. , Czaja, Albert J. , Montaño‐Loza, Aldo J. , Mason, Andrew , Czaja, A J , Montano-Loza, Aldo J , Mazurak, Vera Christine , Lytvyak, Ellina

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 28, 2018 | Volume: 49 | Issue: 2 | Pages: 173-182

10.1111/apt.15029 | PMID 30484857 Get It

SummaryBackgroundVitamin D deficiency has been implicated in the outcome of chronic liver disease.AimTo determine the frequency of severe vitamin D deficiency in autoimmune hepatitis (AIH), assess its association with treatment non‐response, and evaluate the relationship between vitamin D status and liver‐related mortality and need for transplantation.MethodsTwo hundred and nine patients were evaluated by liver tissue examination at presentation. Serum vitamin D levels were determined, and serum levels <25 nmol/L (10 ng/mL) were considered severely deficient. Treatment non‐response was defined as non‐normalised aspartate aminotransferase/alanine aminotransferase and immunoglobulin G levels during conventional immunosuppressive therapy. Univariate and multivariate analyses were performed using binary logistic regression and Cox proportional hazards model.ResultsThe mean vitamin D level was 60 ± 38 nmol/L (range, 3‐263 nmol/L), and 42 patients (20%) had severe vitamin D deficiency. Treatment non‐response was more common in patients with severe vitamin D deficiency than in patients without (59% vs 41%, P = 0.04). Severe vitamin D deficiency was also independently associated with a higher risk of developing cirrhosis (HR 3.40; 95% CI 1.30‐8.87, P = 0.01) and liver‐related mortality or requirement for liver transplantation (LT; HR 5.26, 95% CI, 1.54‐18.0, P = 0.008). Patients with persistent severe deficiency following vitamin D supplementation continued to have poor outcomes.ConclusionsSevere vitamin D deficiency is associated with treatment non‐response, progression to cirrhosis, and liver‐related death or need for LT. Severe vitamin D deficiency is a prognostic biomarker in AIH.
Association Between Early Implant Failure and Prosthodontic Characteristics
Lohse, Christine M. , Muller, Olivia M. , Salinas, Thomas , Carr, Alan B. , Sinha, Nikita, Salinas, Thomas J, Sinha, Nikita

Mayo Clinic

Journal of Prosthodontics | November 28, 2018 | Volume: 28 | Issue: 1 | Pages: 30-35

10.1111/jopr.13003 | PMID 30484925 Get It

AbstractPurposeTo identify associations between early implant failure and prosthodontic characteristics that could be used to guide subsequent continuous quality improvement efforts of patient care.Materials and MethodsAn implant‐level analysis was performed in which data were abstracted from a prospective clinical database of all adult patients treated with implants and followed up from January 2000 through December 2014 at the Department of Dental Specialties at Mayo Clinic in Rochester, Minnesota. These data were used to determine time to implant failure. Associations between prosthodontic characteristics and early implant failure were evaluated with Cox proportional hazards regression models and summarized with hazard ratios (HRs) and 95% confidence intervals (CIs).ResultsAmong 8762 implants in 2787 patients, 395 (4.5%) failed within the first year of placement at a mean (SD) of 127 (97) days (range, 2‐364 days). Univariable analysis showed no associations between early implant failure and use of a cover screw, prosthesis, or definitive or provisional prosthesis at implant placement. Three of 25 single crowns failed, and use of a single crown was significantly associated with early implant failure (HR, 3.94; 95% CI, 1.08‐14.35; P = 0.04). This study identified no significant associations between prosthodontic characteristics identified after implant placement and early implant failure.ConclusionsUse of a prosthesis at implant placement, use of a definitive or provisional prosthesis, and early mechanical complications were not associated with increased risk of early implant failure. Quality improvement efforts should focus on aspects of decision making that aim to decrease surgical complications.